Cargando…

Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer

Immune checkpoint blockade is promising for treating non-small-cell lung cancer (NSCLC). We used multipanel markers to predict the response to immune checkpoint inhibitors (ICIs) by characterizing gene expression signatures or individual genes in patients who showed durable clinical benefit to ICIs....

Descripción completa

Detalles Bibliográficos
Autores principales:	Hwang, Sohyun, Kwon, Ah-Young, Jeong, Ju-Yeon, Kim, Sewha, Kang, Haeyoun, Park, Joonsuk, Kim, Joo-Hang, Han, Ok Jin, Lim, Sun Min, An, Hee Jung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971301/ https://www.ncbi.nlm.nih.gov/pubmed/31959763 http://dx.doi.org/10.1038/s41598-019-57218-9

Ejemplares similares

USP19 and RPL23 as Candidate Prognostic Markers for Advanced-Stage High-Grade Serous Ovarian Carcinoma
por: Kang, Haeyoun, et al.
Publicado: (2021)

Predictive biomarkers for the responsiveness of recurrent glioblastomas to activated killer cell immunotherapy
por: Hwang, Sohyun, et al.
Publicado: (2023)

Granzyme B for predicting the durable clinical benefit of anti-PD-1/PD-L1 immunotherapy in patients with non-small cell lung cancer
por: Chung, Jae Heun, et al.
Publicado: (2022)

Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma
por: Choi, Min Chul, et al.
Publicado: (2020)

Fascin expression is inversely correlated with breast cancer metastasis suppressor 1 and predicts a worse survival outcome in node-negative breast cancer patients
por: Lee, Hye Jin, et al.
Publicado: (2017)

miR-22-3p and miR-30e-5p Are Associated with Prognosis in Cervical Squamous Cell Carcinoma
por: Kwon, Ah-Young, et al.
Publicado: (2022)

T-Cell Receptor Repertoire Characteristics Associated with Prognostic Significance in High-Grade Serous Ovarian Carcinoma
por: Kim, Ju-Won, et al.
Publicado: (2023)

Serum exosomal miRNA-145 and miRNA-200c as promising biomarkers for preoperative diagnosis of ovarian carcinomas
por: Kim, Sewha, et al.
Publicado: (2019)

Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients
por: Farina, Benito, et al.
Publicado: (2023)

Dramatic Response to Cabozantinib in a Patient with Refractory Hepatocellular Carcinoma with c-MET Amplification
por: Sang, Yun Beom, et al.
Publicado: (2023)

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit
por: Wang, Jie, et al.
Publicado: (2019)

Structural Optimization of a Knuckle with Consideration of Stiffness and Durability Requirements
por: Kim, Geun-Yeon, et al.
Publicado: (2014)

Immune‐related signature predicts the prognosis and immunotherapy benefit in bladder cancer
por: Wang, Yejinpeng, et al.
Publicado: (2020)

Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency
por: Pang, Xionghao, et al.
Publicado: (2020)

Breathing silicon anodes for durable high-power operations
por: Hwang, Chihyun, et al.
Publicado: (2015)

A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor
por: Leiserson, Mark D. M., et al.
Publicado: (2018)

Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefit
por: Haberman, Yael, et al.
Publicado: (2023)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020)

Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy
por: Lattanzi, Michael, et al.
Publicado: (2018)

Immunotherapy Plus Locoregional Therapy Leading to Curative-Intent Hepatectomy in HCC: Proof of Concept Producing Durable Survival Benefits Detectable with Liquid Biopsy
por: Raj, Roma, et al.
Publicado: (2023)

Intrahepatic Cholangiocarcinoma with Ductal Plate Malformation-like Feature Associated with Bile Duct Adenoma
por: Kwon, Ah-Young, et al.
Publicado: (2015)

In Situ Oriented Mn Deficient ZnMn(2)O(4)@C Nanoarchitecture for Durable Rechargeable Aqueous Zinc‐Ion Batteries
por: Islam, Saiful, et al.
Publicado: (2021)

CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator
por: Moon, Yong Wha, et al.
Publicado: (2017)

Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity
por: Kim, Kwoneel, et al.
Publicado: (2020)

Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura
por: Boothe, James T., et al.
Publicado: (2017)

Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer
por: Liu, Chengming, et al.
Publicado: (2021)

Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
por: Broos, Katrijn, et al.
Publicado: (2018)

Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
por: Bulen, Benjamin J., et al.
Publicado: (2023)

Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response
por: Kim, Ji-Yeon, et al.
Publicado: (2017)

miR-150 enhances apoptotic and anti-tumor effects of paclitaxel in paclitaxel-resistant ovarian cancer cells by targeting Notch3
por: Kim, Tae Hoen, et al.
Publicado: (2017)

Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade
por: Peng, Jie, et al.
Publicado: (2022)

Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms
por: Liu, Zhichao, et al.
Publicado: (2022)

Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma
por: Wang, Yichen, et al.
Publicado: (2022)

Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
por: Shklovskaya, Elena, et al.
Publicado: (2022)

Genome-wide methylation patterns predict clinical benefit of immunotherapy in lung cancer
por: Kim, Jeong Yeon, et al.
Publicado: (2020)

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy
por: Krueger, Janna, et al.
Publicado: (2021)

Relationship of the lung microbiome with PD-L1 expression and immunotherapy response in lung cancer
por: Jang, Hye Jin, et al.
Publicado: (2021)

Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial
por: Lim, Jaejoon, et al.
Publicado: (2021)

Tumor LAG‐3 and NY‐ESO‐1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non‐small cell lung cancer
por: Jung, Eun Hee, et al.
Publicado: (2021)

Identification and validation of a novel signature for prediction the prognosis and immunotherapy benefit in bladder cancer
por: Zhang, Yichi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bsd6roouds3k0meihhlsod3m3o